Within the framework of the agreement concluded, ASOFARMA will collaborate with Moderna in the management of supply contracts already in force, as well as in the processes of registration of vaccines, support for pharmacovigilance activities, continuing medical education, business governmental, marketing and generation of new agreements that facilitate the availability of SPIKEVAX in the region.
“We are thrilled to partner with Moderna to help patients, physicians and governments in this effort against COVID-19. Moderna is a leading company in the fight against the pandemic, and we are proud to have been chosen as partners for this task, providing all our experience and regional presence,” said Bernardo GiralaGeneral Manager of ASOFARMA Central America and Caribbean.
“This alliance confirms our goal to provide people with innovative treatments that help improve their quality of life and expand vaccination rates in the region,” Girala said.
Moderna Inc., a biotechnology company pioneering the development of messenger RNA (mRNA) therapies and vaccines, has relied on ASOFARMA to enable the arrival in the region of its COVID 19 vaccine, Spikevax .
Moderna’s mRNA platform is based on continuous advancements in basic and applied mRNA science, delivery and manufacturing technology; which has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases.
With this new agreement concluded by ASOFARMA, Moderna Inc. joins a list of international pharmaceutical and biotechnology research and development companies that ASOFARMA has represented in the region for more than twenty years.
SOURCE ASOFARMA CENTROAMERICA AND CARIBE